MedTrace Logo

Comparison of Duac® Gel And Differin® Gel in Mild to Moderate Acne Vulgaris

NCT00160394 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2017-05-30

No results posted yet for this study

Summary

Comparing the efficacy and safety of a gel formulation containing a combination of clindamycin phosphate (equivalent to 1% clindamycin) and benzoyl peroxide (5%) once daily with a gel containing 0.1% adapalene once daily in the treatment of acne vulgaris of mild to moderate severity.

Conditions

  • Acne Vulgaris

Interventions

DRUG

Duac® Gel / Differin® Gel

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Stiefel, a GSK Company

    lead INDUSTRY

Principal Investigators

  • A Chu, MB BS, FRCP · Hammersmith Hospital, London

  • A Langner, MD, DSc · Iwolang spoo, Warsaw

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2005-08-31
Completion
2005-08-31

Countries

  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00160394 on ClinicalTrials.gov